antagonistes des récepteurs del'angiotensine II; hypertension artérielle; angiotensine II; récepteurs de l'angiotensine II
Abstract :
[fr] Dans l'hypertension artérielle et la décompensation cardiaque, les inhibiteurs de l'enzyme de conversion constituent un outil thérapeutique important mais, parfois, au prix de certains effets
secondaires (par exemple, la toux). De nouvelles perspectives de contrôle du système rénine angiotensine-aldostérone se profilent à l'horizon avec l'avènement des antagonistes des récepteurs de l'angiotensine Il. Le losartan est lepremier agent de cette famille, de nature non
peptidique et actif par voie orale. Sa longue durée d'action permet une seule administration par jour. Cet agent bloque tous les effets connus de l'angiotensine II par une action au niveau des
récepteurs appelés AT1. Au vu des premiers résultats publiés, il constitue un concurrent des inhibiteurs de l'enzyme de conversion dans l'hypertension et la décompensation cardiaque.
Dzau JV, Sasamura H, Hein L. Heterogeneity of angiotensin synthetic pathways and recepor subtypes : Physiological and pharmacologi-cal implications. J Hypertens 1993 ; 11 (Suppl. 3) : S13-8.
Burnier M, Waeber B, Brunner R. The advantages of angiotensin II antagonism. J Hypertens 1994 ; 12 (Suppl. 2) : S7-15.
Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists : A new approach to blockage of the renin-angiotensin system. Am Heart J 1994 ; 127 : 1388-401.
de Gasparo M, Bottari S, Levens NR. Characteristics of angiotensin II receptors and their role in cell and organ physiology. In : Laragh JH and Brenner BM eds. Hypertension : pathophysiology, diagnosis and management, second edition. New York : Raven Press Ltd, 1995 : 1695-720.
Brunner HR, Nussberger J, Burnier M, Waeber B. Angiotensin II antagonists. Clin Exper Hypert 1993 ; 15 :1221-38.
Nelson EB, Harm SC, Goldberg M, Shahinfar S, Goldberg A, Sweet CS. Clinical profile of the first angiotensin II (ATI specific) receptor antagonists. In : Laragh JH and Brenner BM eds. Hypertension : Pathophysiology, diagnosis and management, second edition. New York: Raven Press Ltd, 1995 ; 2895-916.
Timmermans PB, Smith RD. Angiotensin II receptor subtypes : Selective antagonists and functional correlates. Eur Heart J 1994 ; 15 (Suppl. D) : 79-87.
Hein L, Barsh G, Pratt R, Dzau V, Kobilka B. Behavioural and cardiovascular effects of diorupting the angiotensin II type-2 receptor gene in mice. Nature 1995 ; 377: 744-7.
Ichiki T, Labosky P, Shiota C, Okuyama S, Imagawa Y, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995 ; 377 : 748-50.
Wong PC, Price WA, Chiu AT, Dunda JV, Carini DJ, Wexler RR, Johnson AJ, Timmermans PB. Nonpeptide angiotensin II receptor antagonists. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exper Therapeutics 1990 ; 252 : 719-25.
Wong PC, Price WA, Chiu AT, Dunda JV, Carini DF, Wexler RR, Johnson AJ, Timmermans PB. In vivo pharmacology of DuP 753. Am J Hypertens 1991 ; 4 : 288s-98s.
Timmermans PB, Wang AT, Chiu AT, Herblin WF, Smith RD. New perspectives in angiotensin system control. J Hum Hypertens 1993 ; 7 (Suppl. 2) : S19-S31.
Siegl PK. Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist. J Hypertens 1993 ; 11 (Suppl. 3) : S19-S22.
Stoll M, Meffert S, Stroth U, Unger T. Growth or antigrowth : Angiotensin and the endothelium. J Hypertens 1995 ; 13 : 1529-34.
Stier CT, Lawrence AA, Levine S, Chanaer PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens 1993; 11 (Suppl. 3) : S37-S42.
Camargo MJ, von Lutterotti N, Campbell WG, Pecker MS, James DJ, et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993 ; 11 : 31-40.
Jover B, Ventre F, Dupont M, Mimram A. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension 1993 ; 21 : 944-8.
Chua BH, Chua CC, Diglio CA, Siu BB. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1993 ; 1178 : 201-6.
Mac Fadyen RJ, Reid JL. Angiotensin receptor antagonists as a treatement for hypertension : Editorial review. J Hypertens 1994 ; 12 : 1333-8.
Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner H. Salt-depenent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993 ; 22 : 339-47.
Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens 1994 ; 7 : 1041-4.
Weber MA, Byyny RL, Pratt JH, Foison EP, Snavely DB, Goldberg AI, Nelson EB. Blood pressure effects of the angiotensin II receptor blocker, Losartan. Arch Int Med 1995 ; 155 : 405-11.
Goldberg MR, Bradstreet TE, Mc Williams EJ, Tanaka WK, Liper S, Bjornsson D, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995 ; 25: 37-56.
Goldberg AI, Dunly MC, Sweet CS. Safety and tolerability of Losartan Potassium, an angiotensin II receptor antagonist, compared with Hydrochlorothiazide, Atenolol, Felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75 : 793-5.
Dickstein K, Gottlieb S, Fleck E, Kostis J, Levine B, De Kock M, Lejemtel T. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994; 12 (Suppl. 2) : S31-S5.
Crozier I, Kram H, Awan N, Cleland J, Stephen S, Dickstein K, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995 ; 91 : 691-7.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the collaborative study group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329 :1456-62.
Burnier M, Brunner HR. Angiotensin II receptor antagonists and the kidney. Current opinion in Nephrology and Hypertension 1994 ; 3 : 537-45.
Erley CM, Scheu M, Wolf S, Braun N, Risler T. Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephrol 1995 ; 43 (Suppl. 1) : S8-S11.
Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994 ; 12 (Suppl. 2) : S37-S42.
Gansevoort T, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system ? Kidney International 1994 ; 45 : 861-7.
Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens 1993 ; 11 (Suppl. 3) : S49-S52.
Lacourciere Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, et al. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994 ; 12 : 1387-93.
